A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension
| Autor: | Donald J. Weidler, Henry R. Black, Robert L. Reeves, David T. Nash, Gustav Schonfeld |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
medicine.medical_specialty
Supine position Diastole urologic and male genital diseases Placebo Placebos Double blind Random Allocation Double-Blind Method Heart Rate Internal medicine medicine Doxazosin Humans In patient Adrenergic alpha-Antagonists Antihypertensive Agents Clinical Trials as Topic business.industry Prazosin Atenolol Lipids Blood pressure Anesthesia Hypertension Cardiology Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | The American Journal of Cardiology. 59:G87-G90 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/0002-9149(87)90164-0 |
| Popis: | The antihypertensive and lipid effects of doxazosin and atenolol were compared in a 10-week, double-blind, parallel, placebo-controlled study. The 129 adults enrolled had mild to moderate hypertension (average supine diastolic blood pressures for doxazosin, atenolol and placebo were 100.6, 101.0 and 99.7 mm Hg, respectively). Patients were randomly assigned to treatment with doxazosin, 1 to 16 mg daily, atenolol, 50 to 100 mg daily or placebo. Among 114 patients included in the efficacy analysis, standing blood pressure (systolic/diastolic) changed by -13/-11 mm Hg with doxazosin (n = 37), -12/-12 mm Hg with atenolol (n = 39) and +1/-1 mm Hg with placebo (n = 38). Mean reductions in blood pressure for doxazosin and atenolol were significantly greater than those for placebo (p less than 0.01), although no statistically significant differences between the active agents were noted. Serum lipid measurements were evaluable for 116 patients, and the 38 doxazosin-treated patients in this group experienced reductions in total cholesterol, total triglyceride and very low density lipoprotein cholesterol levels. Both doxazosin and atenolol demonstrated comparable acceptance profiles. Doxazosin is an effective hypotensive agent with beneficial effects on serum lipid levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|